Drugs /

bay1834942

Back to Drugs List
Associated Genetic Biomarkers

Overview

NCI Definition [1]:
A humanized monoclonal antibody directed against the immune checkpoint regulator carcinoembryonic antigen-related cell adhesion molecule 6 (CEACAM6; CEACAM-6; CD66c), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, anti-CEACAM6 antibody BAY1834942 targets, binds to and blocks the activity of CEACAM6 expressed on various tumor and immune cells, including T-cells. Blocking CEACAM6 signaling abrogates effector T-cell inhibition, activates antigen-specific T-lymphocytes, increases secretion of T-cell cytokines and effector molecules, and enhances cytotoxic T-cell-mediated tumor cell lysis, which results in a reduction in tumor cell proliferation. CEACAM6, an immune checkpoint receptor, is associated with tumor-mediated immune suppression. Elevated CEACAM6 expression is associated with advanced tumor stages and poor prognosis.

Clinical Trials

View Clinical Trials for bay1834942

Bay1834942 has been investigated in 1 clinical trial, of which 0 are open and 1 is closed. Of the trial investigating bay1834942, 1 is phase 1 (0 open).

CEACAM6 Expression is the most frequent biomarker inclusion criterion for bay1834942 clinical trials.

Adenocarcinoma of the gastroesophageal junction, bile duct carcinoma, and bladder carcinoma are the most common diseases being investigated in bay1834942 clinical trials [2].

Top Biomarker Inclusion Criteria for Closed Clinical Trials Investigating Bay1834942
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating bay1834942 and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
bay-1834942, bay 1834942, anti-ceacam6 antibody bay1834942
Drug Categories [2]:
Therapeutic antibodies
Drug Target(s) [2]:
CEACAM6
NCIT ID [1]:
C159609

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.